Continuity Planner

1. Coverage Countdown

This is the first thing people want. They need to know: how many doses they have left, approximately how many weeks of treatment remain, their projected runout date, when they should reorder before they become exposed to a delay, and whether they currently have a safe buffer or not.

This is the core repeat-use behaviour. Every time a person opens a new pen, changes dose, or places an order, the answer changes.

2. Continuity Status

This is the most valuable part. The planner should classify the person into a plain-English planning status such as: Stable continuation, Approaching continuity risk, Gap risk rising, Restart-sensitive, or Maintenance planning now needed.

This creates a strong return reason because people want to know whether their treatment path still looks clean.

3. Restart-Risk Flag

This is where the planner becomes clever. It should not try to prescribe or tell a person what dose they should restart on. That would be the wrong framing. Instead, it should identify planning territory: normal weekly continuation, short delay, meaningful interruption risk, or likely restart-review territory.

This aligns with official and real-world context. Lilly’s UK authorisation materials describe a weekly dosing pathway, and UK people discussing long breaks frequently talk about being treated as restart cases rather than simple continuation cases.

4. Maintenance Timing Prompt

Many people wait too long to think about maintenance. This planner should detect when maintenance planning is becoming relevant by looking at: current BMI, distance from target, rate of recent loss, current dose, whether the person expects to continue long term, and whether the current provider is likely being used mainly for active-loss price rather than long-term fit.

That matters because maintenance planning is easier before the problem becomes urgent.

5. Cost Reality Check

This is the stickiest behavioural layer. The planner should let people compare: current monthly treatment cost, delivery and consultation cost, estimated changes in takeaway spend, changes in alcohol spend, changes in snack or food-delivery spend, reductions in food waste, and the likely cost of a treatment gap or forced restart.

This creates a more honest view of private treatment affordability and reframes thinking away from headline pen price alone toward continuity value.

• You currently have around 7.5 weeks of treatment coverage.
• Your safe reorder window starts on 12 April 2026.
• Your current pattern still looks like stable continuation.
• You are beginning to rely on a low buffer. One delivery delay could push you into a treatment gap.
• This is a good stage to research maintenance-friendly providers before continuity becomes more complicated.
• Your current treatment cost may be partly offset by reduced discretionary food spending, but your low buffer creates continuity risk.

Is the Mounjaro Continuity Planner a medical calculator?

No. It should be presented as a planning and continuity guide, not a clinical decision planner. It helps people organise their situation into a clear continuity picture: how much treatment remains, when to reorder, whether they’re drifting toward a gap, and whether it’s time to think about switching provider or planning for maintenance. It does not provide medical advice, diagnosis, treatment decisions, or dosing recommendations. Think of it as a planning framework that helps you stay ahead of avoidable gaps rather than reacting late.

Why is the Continuity Planner better than a simple injection tracker?

Because it helps with future decisions rather than just recording what already happened. A standard tracker logs injection date, dose, weight, appetite, and side effects—useful but replaceable. A continuity planner answers the decisions people actually return for: “How many weeks do I really have left? Am I too close to a treatment gap? If my next order is delayed, does this still look like continuation? Should I switch before maintenance starts? Is my current provider still the right one for the next stage?” That’s far more valuable than pure logging. It’s the difference between a diary and a planner.

Why is the Continuity Planner especially relevant in the UK?

Because NHS tirzepatide rollout is phased and limited, so many people still depend on private continuity planning. NHS England says tirzepatide access is phased with specialist-service access from 23 March 2025 and tightly limited early primary-care access for those with the highest clinical need. NICE says tirzepatide is available on the NHS only under specific criteria (BMI 35+ and at least 1 weight-related comorbidity) and notes that not everyone will be able to access it immediately during the initial rollout years. That means a large share of the market is still private, where continuity, affordability, reordering, provider switching, and maintenance decisions matter constantly. The planner addresses these UK-specific private-market realities.

Why would people come back to use the Continuity Planner again?

Because their stock, costs, timing, and provider situation change over time, so the result changes too. People revisit when: they place a new order, a provider price changes, they change dose, their BMI changes, they start thinking about maintenance, an order is delayed, they consider switching provider, or they worry they may need to stop temporarily. Every return visit can produce a different output based on their current situation. A one-off calculation may help once. A continuity plan is worth revisiting whenever timing, dose, provider or cost changes. That is why continuity planning is worth revisiting rather than treating as a one-off calculation.